01.24.24 -- Four Keys To Commercial Innovation

Paul Lammers, MD, M.Sc., CEO of Triumvira Immunologics, joins Cell & Gene: The Podcast to talk to Host Erin Harris about TAC, the company's proprietary T cell Antigen Coupler, which has both autologous and allogeneic approaches. They also discuss targeting relapsed or refractory HER2-positive solid tumors and CLDN18.2-positive solid tumors. Tune in to hear a realistic outlook on the evolution of cancer treatment.

This article considers survey findings that illustrate how life sciences companies view and treat technology and how they can be assisted in reaching their goals.

The most difficult clinical research just became more challenging. Learn tactics for how teams can simplify oncology research while solving new and old issues.

There is a significant opportunity for NK cell-based therapies to continue to make a significant impact in patient care. Discover three strategies for creating a cost-effective NK cell biopharma product.

Review the efficacy of fast, stable pools in generating purified product at an early stage, and learn how to accelerate the journey toward first-in-human trials and proof-of-concept studies.